Identification of metabolism-related gene signature in lung adenocarcinoma

被引:1
作者
Wang, Ning [1 ]
Wang, Hui [1 ]
机构
[1] Shandong Univ, Hosp 2, Dept Resp & Crit Care Med, Jinan, Shandong, Peoples R China
关键词
Gene signature; LUAD; nomogram; overall survival; prognostic; TCGA; CANCER PROGRESSION; PROTEIN; PROLIFERATION;
D O I
10.1097/MD.0000000000036267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim:Lung cancer is one of the most common cancers in China and has a high mortality rate. Most patients who are diagnosed have lost the opportunity to undergo surgery. Aberrant metabolism is closely associated with tumorigenesis. We aimed to identify an effective metabolism-related prediction model for assessing prognosis based on the cancer genome atlas (TCGA) and GSE116959 databases.Methods:TCGA and GSE116959 datasets from Gene Expression Omnibus were used to obtain lung adenocarcinoma (LUAD) data. Additionally, we captured metabolism-related genes (MRGs) from the GeneCards database. First, we extracted differentially expressed genes using R to analyze the LUAD data. We then selected the same differentially expressed genes, including 168 downregulated and 77 upregulated genes. Finally, 218 differentially expressed MRGs (DEMRGs) were included to perform functional enrichment analysis and construct a protein-protein interaction network with the help of Cytoscape and Search Tool for the Retrieval of Interacting Genes database. Cytoscape was used to visualize the intensive intervals in the network. Then univariate and Least Absolute Shrinkage and Selection Operator Cox regression analyses, which assisted in identifying the overall survival (OS)-related DEMRGs and building a 10-DEMRG prognosis model, were performed. The prognostic values, tumor immunity relevance, and molecular mechanism were further investigated. A nomogram incorporating signature, age, gender, and TNM stage was established.Results:A 10-DEMRG model was established to forecast the OS of LUAD through Least Absolute Shrinkage and Selection Operator regression analysis. This prognostic signature stratified LUAD patients into low-risk and high-risk groups. The receiver operating characteristic curve and K-M analysis indicated good performance of the DEMRGs signature at predicting OS in the TCGA dataset. Univariate and multivariate Cox regression also revealed that the DEMRGs signature was an independent prognosis factor in LUAD. We noticed that the risk score was substantially related to the clinical parameters of LUAD patients, covering age and stage. Immune analysis results showed that risk score was associated with some immune cells and immune checkpoints. Nomogram also verified the clinical value of the DEMRGs signature.Conclusion:In this study, we constructed a DEMRGs signature and established a prognostic nomogram that is robust and reliable to predict OS in LUAD. Overall, the findings could help with therapeutic customization and personalized therapies.
引用
收藏
页数:11
相关论文
共 59 条
  • [1] Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance
    AlHossiny, Midrar
    Luo, Linlin
    Frazier, William R.
    Steiner, Noriko
    Gusev, Yuriy
    Kallakury, Bhaskar
    Glasgow, Eric
    Creswell, Karen
    Madhavan, Subha
    Kumar, Rakesh
    Upadhyay, Geeta
    [J]. CANCER RESEARCH, 2016, 76 (11) : 3376 - 3386
  • [2] Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol
    Androic, Ilija
    Kraemer, Andrea
    Yan, Ruilan
    Roedel, Franz
    Gaetje, Regine
    Kaufmann, Manfred
    Strebhardt, Klaus
    Yuan, Juping
    [J]. BMC CANCER, 2008, 8 (1)
  • [3] Cell cycle-dependent binding between Cyclin B1 and Cdk1 revealed by time-resolved fluorescence correlation spectroscopy
    Barbiero, Martina
    Cirillo, Luca
    Veerapathiran, Sapthaswaran
    Coates, Catherine
    Ruffilli, Camilla
    Pines, Jonathon
    [J]. OPEN BIOLOGY, 2022, 12 (06)
  • [4] Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial
    Bautista, Francisco
    Paoletti, Xavier
    Rubino, Jonathan
    Brard, Caroline
    Rezai, Keyvan
    Nebchi, Souad
    Andre, Nicolas
    Aerts, Isabelle
    De Carli, Emilie
    van Eijkelenburg, Natasha
    Thebaud, Estelle
    Corradini, Nadege
    Defachelles, Anne-Sophie
    Ducassou, Stephane
    Morscher, Raphael J.
    Vassal, Gilles
    Geoerger, Birgit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3546 - +
  • [5] Adipocyte and lipid metabolism in cancer drug resistance
    Cao, Yihai
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (08) : 3006 - 3017
  • [6] The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma
    Chen, Aifeng
    Ding, Shibiao
    Shen, Xiaoqiang
    Lin, Xuai
    [J]. COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2021, 2021 (2021)
  • [7] Identification of a pyroptosis-related prognostic signature in breast cancer
    Chen, Hanghang
    Luo, Haihua
    Wang, Jieyan
    Li, Jinming
    Jiang, Yong
    [J]. BMC CANCER, 2022, 22 (01)
  • [8] CCAT1/FABP5 promotes tumour progression through mediating fatty acid metabolism and stabilizing PI3K/AKT/mTOR signalling in lung adenocarcinoma
    Chen, Jing
    Alduais, Yaser
    Zhang, Kai
    Zhu, Xiaoli
    Chen, Baoan
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (19) : 9199 - 9213
  • [9] Tetranectin gene deletion induces Parkinson's disease by enhancing neuronal apoptosis
    Chen, Zhifeng
    Wang, Ersong
    Hu, Rong
    Sun, Yu
    Zhang, Lei
    Jiang, Jue
    Zhang, Ying
    Jiang, Hong
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 468 (1-2) : 400 - 407
  • [10] PURIFICATION AND CHARACTERIZATION OF A NOVEL, OLIGOMERIC, PLASMINOGEN KRINGLE 4 BINDING-PROTEIN FROM HUMAN PLASMA-TETRANECTIN
    CLEMMENSEN, I
    PETERSEN, LC
    KLUFT, C
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 156 (02): : 327 - 333